Deprescribing in primary care in Portugal (DePil17-20): a three-phase observational and experimental study protocol

Pedro Augusto Simões, Luiz Miguel Santiago, José Augusto Simões, Pedro Augusto Simões, Luiz Miguel Santiago, José Augusto Simões

Abstract

Introduction: Polypharmacy is commonly defined as the simultaneous taking of five or more drugs. Deprescribing is the process of tapering or stopping medications with the aim of improving patient outcomes and optimising current therapy, and there are several tools aiming at identifying potentially inappropriate medications, especially in the elderly. The direct involvement of patients and their caregivers in the choice and administration of drugs has long been known to be very important, but it is not usually applied. The aim of this study is to assess the knowledge of older adults about deprescription, the effect on willingness to have regular medications deprescribed and its quality-of-life outcome.

Methods and analysis: This study protocol comprises three phases. The first two phases will be nationwide and aim to evaluate the prevalence and patterns of polypharmacy and assess the barriers and facilitators of deprescribing perceived by older adults, as well as their willingness to have regular medications deprescribed and to self-medicate. The third and last phase will be a non-pharmacological randomised clinical study to measure older patients' acceptance to have regular medications deprescribed and related quality of life.

Ethics and dissemination: The study will be conducted in accordance with the principles expressed in the Declaration of Helsinki. It has been approved by the Ethics Committee of the University of Beira Interior and Portuguese National Data Protection Commission. Study results will be published in peer-reviewed journals and presented at national and international conferences. In short, no action will be taken without written consent from patients and doctors.

Trial registration number: > NCT03283735.

Keywords: deprescribing; elderly; polypharmacy; quality of life; willingness.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Gnjidic D, Hilmer SN, Blyth FM, et al. . Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol 2012;65:989–95. 10.1016/j.jclinepi.2012.02.018
    1. Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf 2014;13:57–65. 10.1517/14740338.2013.827660
    1. Machado-Alba JE, Gaviria-Mendoza A, Machado-Duque ME, et al. . Deprescribing: a new goal focused on the patient. Expert Opin Drug Saf 2017;16:111–2. 10.1080/14740338.2017.1273347
    1. Ziere G, Dieleman JP, Hofman A, et al. . Polypharmacy and falls in the middle age and elderly population. Br J Clin Pharmacol 2006;61:218–23. 10.1111/j.1365-2125.2005.02543.x
    1. Field TS, Gurwitz JH, Harrold LR, et al. . Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc 2004;52:1349–54. 10.1111/j.1532-5415.2004.52367.x
    1. Bourgeois FT, Shannon MW, Valim C, et al. . Adverse drug events in the outpatient setting: an 11-year national analysis. Pharmacoepidemiol Drug Saf 2010;19:901–10. 10.1002/pds.1984
    1. Jyrkkä J, Enlund H, Korhonen MJ, et al. . Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 2009;26:1039–48. 10.2165/11319530-000000000-00000
    1. Scott IA, Anderson K, Freeman CR, et al. . First do no harm: a real need to deprescribe in older patients. Med J Aust 2014;201:390–2. 10.5694/mja14.00146
    1. Opondo D, Eslami S, Visscher S, et al. . Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One 2012;7:e43617 10.1371/journal.pone.0043617
    1. Frank C. Deprescribing: a new word to guide medication review. CMAJ 2014;186:407–8. 10.1503/cmaj.131568
    1. Turner JP, Edwards S, Stanners M, et al. . What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open 2016;6:e009781 10.1136/bmjopen-2015-009781
    1. Wahab MS, Nyfort-Hansen K, Kowalski SR. Inappropriate prescribing in hospitalised Australian elderly as determined by the STOPP criteria. Int J Clin Pharm 2012;34:855–62. 10.1007/s11096-012-9681-8
    1. Galazzi A, Lusignani M, Chiarelli MT, et al. . Attitudes towards polypharmacy and medication withdrawal among older inpatients in Italy. Int J Clin Pharm 2016;38:454–61. 10.1007/s11096-016-0279-4
    1. Qi K, Reeve E, Hilmer SN, et al. . Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm 2015;37:949–57. 10.1007/s11096-015-0147-7
    1. Scott IA, Hilmer SN, Reeve E, et al. . Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015;175:827–34. 10.1001/jamainternmed.2015.0324
    1. Jansen J, Naganathan V, Carter SM, et al. . Too much medicine in older people? Deprescribing through shared decision making. BMJ 2016;353:i2893 10.1136/bmj.i2893
    1. Reeve E, Shakib S, Hendrix I, et al. . Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol 2014;78:738–47. 10.1111/bcp.12386
    1. Whitman AM, DeGregory KA, Morris AL, et al. . A Comprehensive Look at Polypharmacy and Medication Screening Tools for the Older Cancer Patient. Oncologist 2016;21:723–30. 10.1634/theoncologist.2015-0492
    1. Page AT, Clifford RM, Potter K, et al. . The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;82:583–623. 10.1111/bcp.12975
    1. Beer C, Loh PK, Peng YG, et al. . A pilot randomized controlled trial of deprescribing. Ther Adv Drug Saf 2011;2:37–43. 10.1177/2042098611400332
    1. Reeve E, Shakib S, Hendrix I, et al. . The benefits and harms of deprescribing. Med J Aust 2014;201:386–9. 10.5694/mja13.00200
    1. Ryan R, Hill S. Making rational choices about how best to support consumers’ use of medicines: a perspective review. Ther Adv Drug Saf 2016;7:159–64. 10.1177/2042098616651198
    1. Gnjidic D, Le Couteur DG, Kouladjian L, et al. . Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med 2012;28:237–53. 10.1016/j.cger.2012.01.006
    1. Duerden M, Avery T, Payne R. Polypharmacy and medicines optimisation Making it safe and sound. Kings Fund [Internet] 2013:1–68 .
    1. Stiggelbout AM, Van der Weijden T, De Wit MP, et al. . Shared decision making: really putting patients at the centre of healthcare. BMJ 2012;344:e256 10.1136/bmj.e256
    1. Reeve E, Wiese MD, Hendrix I, et al. . People’s attitudes, beliefs, and experiences regarding polypharmacy and willingness to Deprescribe. J Am Geriatr Soc 2013;61:1508–14. 10.1111/jgs.12418
    1. Reeve E, To J, Hendrix I, et al. . Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging 2013;30:793–807. 10.1007/s40266-013-0106-8
    1. Batel-Marques F, Mendes D, Alves C, et al. . [Pharmacovigilance in Portugal: Activity of the Central Pharmacovigilance Unit]. Acta Med Port 2015;28:222–32.
    1. Prazeres F, Santiago L. Prevalence of multimorbidity in the adult population attending primary care in Portugal: a cross-sectional study. BMJ Open 2015;5:e009287 10.1136/bmjopen-2015-009287

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner